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Introduction: The scope of extracorporeal membrane oxygenation (ECMO) is expanding; however, optimal drug
prescription during ECMO remains a developing science. Currently, there are no clear guidelines for antibiotic
dosing during ECMO. This open-label, descriptive, matched-cohort pharmacokinetics (PK) study aimed to compare
the PK of meropenem in ECMO patients to critically ill patients with sepsis not receiving ECMO (controls).
Methods: Eleven adult patients on ECMO (venovenous (VV) ECMO, n = 6; venoarterial (VA) ECMO, n = 5) receiving
intravenous (IV) meropenem were included. Meropenem plasma concentrations were determined using validated
chromatography. Population PK analysis was performed using non-linear mixed effects modelling. This data was
compared with previously published meropenem PK data from 10 critically ill adult patients not on ECMO (preserved
renal function (n = 5) or receiving renal replacement therapy (RRT) (n = 5). Using these data, we then performed Monte
Carlo simulations (n = 1,000) to describe the effect of creatinine clearance on meropenem plasma concentrations.
Results: In total, five (two VV, three VA) out of eleven ECMO patients received RRT. The other six patients (four VV, two
VA) had no significant impairment in renal function. A two-compartment model adequately described the data. ECMO
patients had numerically higher volume of distribution (0.45 ± 0.17 versus 0.41 ± 0.13 L/kg, P = 0.21) and lower clearance
compared to controls (7.9 ± 5.9 versus 11.7 ± 6.5 L/h, P = 0.18). Variability in meropenem clearance was correlated with
creatinine clearance or the presence of RRT. The observed median trough concentrations in the controls were 4.2 (0.0
to 5.7) mg/L. In ECMO patients, while trough meropenem concentrations >2 mg/L were achieved in all patients, a
more aggressive target of >8 mg/L for less susceptible microorganisms was observed in only eight out of eleven
patients, with five of them being on RRT.
Conclusions: ECMO patients exhibit high PK variability. Decreased meropenem CL on ECMO appears to compensate
for ECMO and critical illness-related increases in volume of distribution. Routine target concentrations >2 mg/L are
maintained with standard dosing (1 g IV 8-hourly). However, an increase in dose may be necessary when targeting
higher concentrations or in patients with elevated creatinine clearance.* Correspondence: kiran.shekar@health.qld.gov.au
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Extracorporeal membrane oxygenation (ECMO) is being
increasingly used in adult patients with acute severe car-
diorespiratory failure as a supportive therapy [1,2]. Pro-
longed support for bridge to recovery or transplantation is
now possible. While ECMO sustains life, stabilises physi-
ology and allows time for definitive management, little is
known about the independent effects of ECMO on anti-
biotic pharmacokinetics (PK). ECMO is thought to further
complicate the PK alterations seen during critical illness
[3], which appears to manifest as increased volume of dis-
tribution (Vd) and decreased clearance (CL) [4]. Ex vivo,
animal [5,6] and clinical studies [7] are currently underway
to further investigate the PK changes seen during ECMO
and to develop evidence-based dosing guidelines. Simu-
lated ex-vivo studies that utilised adult circuitry [8] have
demonstrated significant antibiotic drug sequestration in
the circuit based on physicochemical properties of individ-
ual drugs. However, the PK data on antibiotics in critically
ill adult patients is limited with available studies indicating
significant PK alterations [3,9,10]. This is concerning as the
risks of suboptimal drug dosing (both under- and overdos-
ing) are profound in this complex group of patients who
have high infection-related mortality.
A significant number of patients receive ECMO for se-
vere cardiac and/or respiratory failure resulting from in-
fectious aetiologies. Patients may develop new infection
during ECMO support. Studies indicate that infections
occur frequently during ECMO and infections/colonisa-
tion with multi-drug-resistant organisms is not uncom-
mon [11-13]. Gram-negative bacteria are responsible for
significant proportions of these infections acquired dur-
ing ECMO [11]. Meropenem is used as an empirical or
targeted broad-spectrum antibiotic in this setting. It is a
minimally protein-bound and hydrophilic drug that under-
goes significant sequestration/degradation in ex vivo ECMO
circuit models [8]. In this setting, one would anticipate pro-
found alterations in meropenem PK in patients on ECMO,
although to date, we are unaware of any studies to guide
meropenem dosing in adults on ECMO.
This open-label, descriptive, matched-cohort PK study
aimed to describe single-dose meropenem PK during
ECMO using critically ill patients with sepsis and not re-
ceiving ECMO as controls.
Materials and methods
Participants and data collection
This study was conducted at a 650-bed university-affiliated
tertiary referral hospital. The ICU is a 27-bed mixed ICU
with a predominantly cardio-thoracic cohort. There is an
antibiotic stewardship programme with twice weekly ward
rounds by an infectious diseases physician. Infection con-
trol practices include review of all healthcare-associated
bacteraemia and multiple-resistant organism screening.Ethics approval was obtained from the Prince Charles Hos-
pital Ethics Committee, Brisbane, QLD, Australia (HREC/
11/QPCH/121). Informed consent was obtained from the
study participants or surrogate decision makers as applic-
able. The study protocol has been published and detailed
methodology, inclusion and exclusion may be found else-
where [7]. Eligible patients ≥18 years of age and receiving
meropenem during their ECMO therapy were recruited.
Known allergy to study drug, pregnancy, serum bilurubin
concentration >150 μmol/L, ongoing massive blood trans-
fusion requirement (>50% blood volume transfused in the
previous 8 hours) and therapeutic plasma exchange in the
preceding 24 hours were exclusion criteria. Data re-
lated to patient demographics, renal and hepatic func-
tion, details of ECMO and renal replacement therapy
(RRT) were collected.
Details of ECMO and RRT support
Patients received either venovenous (VV) or peripheral
venoarterial (VA) ECMO as clinically indicated. The
standardised ECMO circuitry comprised of Bioline tub-
ing, Quadrox D oxygenator and a centrifugal pump (Jostra
Medizintechnik AG, Hirrlingen, Germany). The prime
volume was 668 mL and the circuits were freshly primed
with Plasmalyte 148 (Baxter, Sydney, NSW, Australia)
followed by Albumex 4% (human albumin, 40 g/L; CSL
Bioplasma, Melbourne, VIC, Australia). RRT was provided
as extended daily diafiltration (EDD-f) to ECMO patients
using a Fresenius haemodialysis machine (4008 s ARrT
plus, Fresenius Medical Care, Bad Homburg, Germany)
that was connected to the post-oxygenator site of the
ECMO circuit using Fresenius AV600S filters. The blood
flow (200 to 300 mL/min) and dialysate flow rates (200 mL/
min) and duration were standardised (6 to 8 hours).
Continuous venovenous haemofiltration (CVVHF) was
performed in the control group RRT patients [14] using
the Nephral ST500 (AN69 hollow-fibre) filter with a sur-
face area of 2.15 m2. All patients were initiated on the
CVVHF at least 8 hours prior to the sampling period. The
ultrafiltrate rate was set between 66 and 100 mL/min, with
a target blood flow rate of 250 mL/min.
Controls
Previously published meropenem PK data were used for
the historical controls (n = 10). Five patients with sepsis
and no renal dysfunction receiving intermittent infusions
of meropenem were included [15] from one study. The
remaining five patients were the first five recruited to a
PK study (n = 10) examining meropenem PK in high-
volume continuous RRT [14].
Meropenem dosing and measurements
Meropenem dosing in ECMO patients was at the discre-
tion of the clinician, based on the clinical context and
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administered prior to PK sampling in the ECMO pa-
tients; 1 g intravenous (IV) bolus and 1 g IV q8h (n = 8),
1.5 g IV bolus and 1 g IV q8h (n = 2), 2 g IV bolus and
1 g IV q8h (n = 1). None of the RRT-dependent patients
received an additional dose post RRT. Doses were recon-
stituted in 10 mL of diluent and given as IV bolus infu-
sion in 50 mL over 30 minutes. The control patients
[15] with preserved renal function (n = 5) were given a
1.5 g meropenem first dose (in 10 mL of water-for-
injection infused by central line over 5 minutes) and
then 1 g (in 10 mL of water-for-injection infused by
central line over 3 minutes) every 8 hours. Controls
with impaired renal function on high-volume CVVHF
[14] received meropenem as 1 g (in 20 mL of water-
for-injection infused by central line over 3 minutes)
every 8 hours.
Blood sampling in ECMO patients was undertaken at
predose, 15, 30, 45, 60, 120, 180, 360 and 480 minutes.
In controls with preserved renal function [15], samples
were collected at predose, 3, 5, 7, 10 15, 20, 30, 45, 60,
90, 150, 240, 360 and 480 minutes. In controls on
CVVHF [14], sampling was performed at predose, and
at 15, 30, 45, 60, 120, 240, and 480 minutes. All samples
were immediately refrigerated at 4°C, and plasma was
separated and frozen at 80°C within 24 hours of sample col-
lection. The blood samples were centrifuged at 3,000 rpm
for 10 minutes.
Meropenem analysis was conducted on a Shimadzu
Prominence high-performance liquid chromatography
(HPLC) system (Shimadzu Corp, Kyoto, Japan) with a
Waters XBridge C18 column stationary phase (Waters
Corp, Milford, MA, USA). The mobile phase was 4%
acetonitrile/96% phosphate buffer 50 mM at pH 2.5 and
the eluent was measured by UV at 304 nm. The internal
standard for the HPLC assay was ertapenem. HPLC as-
says had inter- and intra-day reproducibility of 5.6% and
0.6%, respectively. The limit of quantification for mero-
penem was 1.0 mg/L and the coefficient of correlation
for the assay was 1.000.
Population pharmacokinetic analysis
The concentration-time data for meropenem in plasma
were fitted using a non-linear mixed-effects modeling
approach (NONMEM version 7.3, Globomax LLC,
Hanover, MD, USA) [30]. A Digital Fortran compiler was
used and the runs were executed using Wings for NON-
MEM [16]. Data were analysed using the first-order condi-
tional estimation method with interaction (ADVAN3).
Between-subject variability (BSV) was calculated using
an exponential variability model and was assumed to fol-
low a log-normal distribution. Residual unexplained vari-
ability (RUV) was modeled using a combined exponential
and additive random error model. Visual inspection ofdiagnostic scatter plots and the NONMEM objective
function value (OFV) were used to evaluate goodness of
fit. Statistical comparison of nested models was under-
taken in the NONMEM program on the basis of a χ2 test
of the difference in OFV. A decrease in the OFV of 3.84
units (P <0.05) was considered statistically significant. De-
creases in BSV of one of the parameters of at least 10%
were also accepted for inclusion of a more complicated
model. Specifically, we calculated central volume of distri-
bution (Vc), peripheral volume of distribution (Vp), total
indexed volume of distribution (Vd), inter-compartmental
clearance (Q) and meropenem CL using NONMEM.Population pharmacokinetic model diagnostics
Visual inspection of diagnostic scatter plots and the
NONMEM OFV were used to evaluate goodness of fit.
Statistical comparison of nested models was undertaken
in the NONMEM program using log-likelihood ratios,
which are assumed to be chi-square distributed. On the
basis of a χ2 test of the difference in OFV, a decrease in
the OFV of 3.84 units (P <0.05) for one degree of free-
dom was considered statistically significant. Decreases in
BSV of one of the parameters of at least 10% were also
accepted for inclusion of a more complicated model.Population pharmacokinetic covariate screening
Covariate model building was performed in a stepwise fash-
ion with forward inclusion and backward deletion based
upon the aforementioned model selection criteria. Age, sex,
weight, serum creatinine concentration, Cockroft-Gault-
calculated creatinine clearance (CrCL) as well as presence
of ECMO and RRT were evaluated as covariates.Population pharmacokinetic bootstrap
A non-parametric bootstrap method (n = 1,000) was used
to study the uncertainty of the pharmacokinetic parameter
estimates in the final model. From the bootstrap empirical
posterior distribution, we have been able to obtain the
95% confidence interval (2.5 to 97.5% percentile) for the
parameters, as described previously [17].Dosing simulations
We performed Monte Carlo simulations (n = 1,000) to
describe the effect of five different CrCL on meropenem
concentrations in a 50-year-old, 80 kg male receiving
ECMO. The CrCL simulated were at 20, 50, 80, 120 and
180 mL/min. We simulated the following doses 1 g IV
8-hourly, 500 mg IV 8-hourly and 2 g IV 8-hourly.
While interpreting the simulations, a trough meropenem
concentration of 2 mg/L and 8 mg/L was considered op-
timal for treating susceptible and less susceptible patho-
gens, respectively [18].
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Statistical analyses were performed using the SPSS 13.0 for
Windows NT software package (SPSS Inc., Chicago, IL,
USA, 2004). Discrete variables were expressed as counts
(percentage) and continuous variables as means ± standard
deviation (SD) or median (25th to 75th percentiles). Demo-
graphics and clinical differences between study groups
were assessed using a chi-square, Fisher’s exact test, Stu-
dent’s t test, or Mann-Whitney U test, as appropriate. A
P <0.05 was considered to be statistically significant.
Results
Five (two VV, three VA) out of eleven ECMO patients re-
ceived RRT. The other six patients (four VV, two VA) had
no significant impairment in renal and hepatic functions,
based on routine biochemical parameters. The indications
for ECMO included pneumonia, septic shock (n = 7); cardio-
genic shock (n = 2); sickle-cell crisis (n = 1); primary graft
dysfunction post lung transplant (n = 1). The median se-
quential organ failure assessment scores were not signifi-
cantly different between the controls and ECMO patients (7
[3-15] vs. 13 [9-15,17,18], respectively, P= 0.14). The demo-
graphic and clinical data are summarised in Table 1. Median
time to PK sampling in ECMO patients was 2 days (1 to 7).
Meropenem concentrations and PK parameters in
controls and ECMO patients
The median observed peak concentrations (Cmax) and





Age (years) 55.0 (48–61)
Total body weight (kg) 80 (75–85)
Mechanical ventilation 5/5
Type of ECMO (VA/VV) 0/0
Day 1 SOFA score 3 (3–4)
Plasma creatinine concentration (μmol/L) 73 (55–101)
Creatinine clearance (mL/min) 106 (98–127)
RRT mode -
Serum bilirubin (μmol/L) 9 (5–23)
Serum albumin (g/L) 22 (18–36)
Serum proteins (g/L) 56 (55–70)
Meropenem daily dose (g) 1 q 8 h
Plasma C max (mg/L) 93 (74–119)
Plasma C min (mg/L) 0 (0–2)
*Patients RRT dependent. The biochemical indices were measured on day of pharm
membrane oxygenation; RRT, renal replacement therapy; VA, venoarterial; VV, veno
venovenous haemofiltration; EDD-f, extended daily diafiltration.were 65.4 (58.7 to 74.4) mg/L and 4.2 (0.0 to 5.7) mg/L
respectively. The ECMO group achieved a median Cmax
of 55.3 (37.8 to 60.4) mg/L and a Cmin of 7.2 (4.0 to
17.2) mg/L; 10 out of 11 ECMO patients maintained a
Cmin >2 mg/L between doses. ECMO patients had a nu-
merically higher, but non-statistically significant volume
of distribution (0.45 ± 0.17 vs. 0.41 ± 0.13 L/kg, P = 0.21)
and lower clearance compared to controls (7.9 ± 5.9 vs.
11.7 ± 6.5 L/h, P = 0.18). In ECMO patients, while trough
meropenem concentrations of >2 mg/L were achieved in
all patients, a more aggressive strategy of >8 mg/L tar-
geting less susceptible microorganisms was maintained
only in eight out of eleven patients, with five of them be-
ing on RRT.
Pharmacokinetic model building
The time course of plasma meropenem concentrations
was best described by a two-compartment linear model
with combined residual error and BSV on Vc, Vp and
CL. This model included zero order input of drug into
the central compartment. The mean parameter esti-
mates from the final covariate model as well as the
95% confidence intervals from all bootstrap runs are
shown in Table 2. The goodness-of-fit plots are shown
in Figure 1.
After screening all relevant biologically plausible co-
variates, the following covariates were included in the
final model. RRT was included for CL with Cockroft-
Gault CrCL for CL in patients not receiving RRT. WhenECMO
RRT No RRT RRT
(n = 5) (n = 6) (n = 5)
3/2 1/5 3/2
56 (46–66) 29 (16–46) 38 (23–56)
70 (60–100) 69 (60–80) 70 (70–76)
5/5 5/5 5/5
0/0 3/3 2/3
15 (14–16) 9 (7–14) 16 (13–17)
na* 75 (44–82) na*
na* 108 (65–183) na*
CVVH - EDD-f
93 (36–115) 23 (9–73) 58 (34–134)
26 (23–36) 31 (27–35) 24 (22–32)
62 (60–65) 49 (46–54) 44 (34–56)
1 q 8 h 1 q 8 h 1q 8 h
58 (52–68) 42 (27–56) 59 (50–86)
7.5 (5–18) 4.9 (2–10) 18 (7–43)
acokinetic sampling. Data are presented as median (IQR). ECMO, extracorporeal
venous; SOFA, sequential organ failure assessment; CVVH, continuous
Table 2 Mean parameter estimates and bootstrap mean
(95% confidence interval) estimates for the final
covariate model
Parameter Model Bootstrap
Mean Mean 95% confidence interval
2.5% 97.5%
Fixed effects
CL (L/h) 5.1 5.4 3.7 7.4
Vc (L) 18.7 18.2 13.0 21.0
Vp (L) 13.2 13.6 11.3 15.9
Q (L/h) 21.0 24.2 12.8 37.0
CLCRCL 1.89 1.85 0.99 2.65
Random effects BSV (% CV)
CL (L/h) 51.6 52.2 37.9 66.6
Vc (L) 45.8 48.4 32.1 69.9
Vp (L) 28.7 16.2 0.2 42.1
Random error
RUV (% CV) 13.7 13.3 10.1 17.6
RUV (SD, mg/L) 2.3 1.87 1.02 2.70
CL, clearance; Vc, volume of distribution of the central compartment; Vp,
volume of distribution of the peripheral compartment; Q, inter-compartmental
clearance; CLCRCL, the fractional effect of CrCL on CL for patients not receiving






















































Figure 1 Goodness-of-fit plots for the final covariate meropenem
pharmacokinetic model. The top panel presents the population
predicted concentrations versus the observed concentrations. The lower
panel presents the individual predicted concentrations versus the
observed concentrations. For both graphs, the dashed line
represents the lines of best fit that have acceptable correlations
(r2 = 0.96, P <0.0001 for population predicted concentrations and
r2 = 0.64, P <0.0001, for the individual predicted concentrations
using linear regression).
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the OFV reduced statistically significantly (P <0.05) and
the goodness-of-fit plots improved. Inclusion of ECMO
as a covariate on any parameter did not improve the good-
ness of fit of the model nor was it statistically significant.
The final covariate model for the two-compartment mero-
penem model was represented by the following equation:
TVCL ¼ θ1: CLRRTð Þ þ θ1: CLNORRT  CrCLð Þ
Where TVCL is the typical value of meropenem clear-
ance where CLRRT is 0 for patients not receiving RRT
and CLNORRT is 0 for patients receiving RRT. CrCL is
Cockroft-Gault-calculated creatinine clearance and θ1 is
the typical population value for clearance.
Dosing simulations
Figure 2 (a-c) shows the mean concentration-time curves
for the 1,000 simulated patients for each dose and CrCL
and highlights the importance of CrCL in meropenem
dosing. Table 3 reports the mean and 10th percentile
trough concentrations for the simulated regimens. This
table demonstrates the wide PK variability present in the
studied patients as evidenced by the profound difference
in the values described. From this data, patients with the
following CrCL should receive the corresponding doses to
ensure 90% of patients maintain concentrations above
2 mg/L throughout the entire dosing interval, 20 to50 mL/min - 500 mg 8-hourly, 80 to 180 mL/min - 1 g
8-hourly, >180 mL/min - 2 g 8-hourly.
Discussion
This study provides preliminary evidence that standard
meropenem dosing (1 g IV 8-hourly) as an intermittent
bolus infusion in ECMO patients is likely to result in
drug concentrations sufficient to treat highly susceptible
Gram-negative pathogens. Conventional-dose meropenem
should achieve a time over minimal inhibitory concentra-
tion (T>MIC) of 100%, assuming a minimum inhibitory
concentration (MIC) of 2 mg/L (the European Committee
on Antimicrobial Susceptibility Testing (EUCAST) for
Figure 2 Simulated mean meropenem logarithmic concentrations
in a critically ill patient on ECMO with CrCL of 20, 50, 80, 120 and
180 mL/min for (a) 500 mg IV 8-hourly, (b) 1 g IV 8-hourly and
(c) 2 g IV 8-hourly. CrCL, creatinine clearance; ECMO, extracorporeal
membrane oxygenation.
Table 3 The effect of changing creatinine clearance on
mean (50th percentile) and 10th percentile trough
concentrations from the simulated ECMO patients












20 50th 18.9 26.4 76.4
10th 3.6 16.2 14.6
50 50th 14.5 19.7 58.8
10th 2.6 9.8 10.5
80 50th 10.0 14.8 39.7
10th 1.3 4.8 5.1
120 50th 7.6 11.1 30.0
10th 0.7 2.5 2.7
180 50th 5.6 7.9 21.7
10th 0.4 0.7 0.9
These simulations assume that no significant accumulation of meropenem
occurred in study population. ECMO, extracorporeal membrane oxygenation.
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susceptible P. aeruginosa (MIC90 8 mg/L) and Acineto-
bacter species (MIC90 16 mg/L) higher meropenem
doses would have to be considered especially in pa-
tients with elevated CrCL. Given that, patients on
ECMO have decreased CL in most cases [3], standard
dosing is likely to achieve target plasma concentrations
in most patients. This is important considering the po-
tential clinical and bacteriological benefits of maintain-
ing 100% T>MIC in critically ill patients [19].
This study uses meropenem plasma concentration data
from four different patient populations to perform ro-
bust dosing simulations and to provide preliminary in-
sights into the incremental effects of critical illness,
ECMO and RRT on meropenem PK. The plasma con-
centrations observed in ECMO patients reflect a balancebetween the independent alterations in Vd and CL that
occur in the presence of critical illness [20], organ fail-
ures and ECMO [3]. Interestingly in this study, routinely
targeted meropenem plasma concentrations (>2 mg/L)
were maintained with standard dosing, both in ECMO
patients on RRT and those with preserved renal func-
tion. However, plasma meropenem concentrations were
significantly higher in the RRT group when compared to
patients with preserved renal function. This is important
as standard dose adjustments for renal impairment (for
example IV 500 mg 8-hourly or 1 g 12-hourly) in these
patients receiving RRT may potentially result in under
dosing. Equally, use of higher than standard doses may
precipitate the risk of toxicity. Therapeutic drug moni-
toring where available may further improve the safety
and efficacy of meropenem dosing during ECMO [4,21].
ECMO patients demonstrated reduced meropenem CL
and an increased Vd when compared with controls, but
these changes were not statistically significant. This
trend is consistent with the PK changes expected during
ECMO based on available literature [3]. An increase in
Vd resulting from critical illness [20] and sequestration
in the ECMO circuit [8] can significantly affect plasma
concentrations probably of meropenem, a hydrophilic
with limited protein binding and predominant renal CL.
Equally, AKI is common in patients on ECMO, with
incidence as high as 70% to 85% in single-centre stud-
ies [22]. The Extracorporeal Life Support Organisation
(ELSO) Registry data [23] suggests that up to 46% of
patients on VV ECMO and 44% on VA ECMO may re-
quire some form of RRT during the ECMO run. There
is significant variability in mode of RRT used in ECMO
patients and this may appear to limit the generalisability
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our dosing simulations that account for a range (20 to
180 mL/min) of net CrCL (native and RRT) achieved in
ECMO patients However, dosing may not be entirely
based on CL achieved during RRT and possible residual
renal CL or extra renal CL may have to be considered.
This is of high relevance during ECMO as meropenem
can undergo significant degradation/sequestration during
their transit through the ECMO circuit. Although upregu-
lated non-renal elimination is possible for ciprofloxacin in
renally impaired patients [24], there is no data to support
this in the case of meropenem.
In this study the estimated median meropenem CL
seen in controls on CVVHF was 3.5 (3 to 4) L/h. There
is no reliable data on meropenem CL during EDD-f even
in non-ECMO patients and it is highly likely that this
will be greater than seen with high-volume CVVHF.
Despite RRT partially compensating for decreased drug
CL in patients with ECMO and acute kidney injury
(AKI), they maintained significantly higher meropenem
concentrations during the entire dosing interval with
standard dosing when compared with patients without
RRT and the controls. Our simulations confirm that a
meropenem dose of 500 mg - 1 g 8-hourly will provide a
plasma concentration >2 mg/mL in 90% of the patients
with CrCL ranging from 20 to 180 mL/min. Given the
relatively wide therapeutic index of meropenem, highly
variable CrCL between ECMO patients based on modal-
ity and intensity of RRT used, loss in the ECMO circuit
and preponderance of less susceptible organisms in this
population especially with prolonged ECMO support, a
dose of 1 g 8-hourly may be considered appropriate till
more PK data becomes available. Meropenem accumula-
tion and under dosing are still potential concerns in pa-
tients with extremes of CL and these high-risk groups
need to be specifically addressed in future PK studies in
this population.
The findings of this study contradict the available
sparse data pertaining to meropenem PK during ECMO.
To our knowledge, there are no previously published PK
studies in neonatal or adult patients on ECMO. A recent
case report [9] indicated heightened meropenem CL
(20.8 L/h) and Vd (0.56 L/kg) during ECMO and RRT
and a high-dose meropenem infusion was utilised to
maintain optimal concentrations. However, the CL for
meropenem in the current study was significantly
lower (7.3 ± 5.6 L/h) and the Vd was highly comparable
(0.53 ± 0.17 L/kg). However, it should be noted that
meropenem is unstable at 37°C and ongoing exterio-
rization of blood during ECMO may lead to a degree of
spontaneous degradation, which can be erroneously inter-
preted as increased CL. While it is challenging to arrive at
any strong conclusions based on these data, it appears that
eventual success of meropenem regimens during ECMOmay rely more on the CL that occurs in an individual
patient.
There is emerging data to suggest that the commonly
used dose of meropenem (1 g 8-hourly) may be suffi-
cient to treat an unselected population of septic critically
ill patients not receiving ECMO or RRT [25]. In this set-
ting, the risk of under dosing with 1 g 8-hourly dosing
in critically ill patients on ECMO and with preserved
renal function appears small and augmented renal clear-
ance [26] has not yet been described in this population.
However, patients on peripheral VA ECMO in whom ox-
ygenated blood is being returned into iliac artery or dis-
tal aorta may experience very high non-pulsatile renal
blood flows and whether this result in heightened CL in
patients with preserved renal function needs further
evaluation.
The current study has limitations. Characterizing al-
tered PK in patients receiving RRT while on ECMO can
be complex. Variability in the techniques used for RRT
and ECMO is a significant limitation in the generalis-
ability of our results. Future studies should further inves-
tigate the effects of type and intensity of RRT chosen on
meropenem PK during ECMO. Despite the ECMO
population being small and heterogeneous, our model
could accurately predict drug concentrations in ECMO
patients and controls and discriminated well for RRT.
This study does not address the pharmacodynamic as-
pects of meropenem therapy and no meaningful clinical
outcome measures can be generated from the small
sample. The non-ECMO patients selected were consid-
ered to be optimal controls for patients on ECMO who
exhibited systemic inflammatory syndrome with or with-
out clear evidence of infection. Systemic inflammation is
known to significantly affect volume of distribution of
the hydrophilic and renally excreted drugs such as mero-
penem [20]. Hepatic and renal function, however, were
not matched as a clear separation between controls and
ECMO patients who had preserved renal function and
ECMO patients who were dialysis dependent, desirable
in the context of this study, which sought to highlight
the influence of inflammation and illness, ECMO and
RRT.
Conclusions
In patients receiving meropenem on ECMO, standard
dosing (1 g 8-hourly) should achieve routinely targeted
plasma concentrations. However, an increase in dose
may be necessary when targeting higher plasma concen-
trations (>4x MIC and 100% T>MIC) and or in patients
with elevated creatinine clearance. Future PK studies
should validate these findings especially in ECMO pa-
tients with extremes of CrCL (<20 or >150 mL/min).
Therapeutic drug monitoring where possible is recom-
mended until robust dosing guidelines become available.
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 ECMO patients exhibit high PK variability.
 Standard meropenem dosing (1 g IV 8-hourly) during
ECMO achieved usual target trough concentrations
of >2 mg/L both in patients with preserved renal
function and in those on RRT.
 Standard meropenem dosing (1 g IV 8-hourly)
during ECMO may not achieve higher target MICs
(>8 mg/L), especially in patients with preserved
renal function.
 Clinicians need to consider the presence of ECMO,
renal function or RRT and microbiological
characteristics when choosing doses for patients
 Therapeutic drug monitoring (TDM) is
recommended where possible
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